Ketorolac
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ketorolac: From Acute Pain Management to Headache Disorder
One-Sentence Summary
Ketorolac is an NSAID (nonsteroidal anti-inflammatory drug), a class that has been broadly established for short-term management of moderate-to-severe acute pain; detailed original-indication text was not captured in this evidence pack. The TxGNN model predicts it may also be effective for Headache Disorder (migraine/tension-type headache), a use already supported by 37 clinical trials and 19 publications, including a 2026 American Headache Society guideline update. Two weaker candidate indications — Rosacea Conjunctivitis and Trigeminal Autonomic Cephalalgia — are also flagged by the model but have little to no supporting evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute pain management (NSAID class; detailed original-indication text not on file) |
| Predicted New Indication | Headache Disorder |
| TxGNN Prediction Score | 99.43% |
| Evidence Level | L1 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, ketorolac is a member of the NSAID class, acting via non-selective inhibition of cyclooxygenase (COX-1/COX-2) to reduce prostaglandin synthesis; its efficacy in acute pain has been well established for decades.
Headache disorders such as migraine and tension-type headache involve neurogenic inflammation and prostaglandin-mediated nociception in the trigeminovascular pathway. The anti-inflammatory/analgesic mechanism that underlies ketorolac's approved pain indication therefore plausibly extends to headache pain — and in practice, parenteral ketorolac is already a long-standing off-label/guideline-referenced option in emergency-department migraine management, which is consistent with the very large volume of trial and literature evidence identified below.
Clinical Trial Evidence
(Top 10 of 37 trials identified, prioritizing completed/higher-phase, headache-specific studies)
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01807234 | Phase 4 | Completed | 72 | Ketorolac nasal spray vs. sumatriptan nasal spray vs. placebo for acute migraine treatment, including migraine-associated nausea/allodynia |
| NCT02358681 | Phase 3 | Completed | 59 | Intranasal vs. intravenous ketorolac non-inferiority trial for pediatric migraine |
| NCT00483717 | Phase 2 | Completed | 173 | Safety, tolerability, and analgesic efficacy of intranasal ketorolac for acute migraine |
| NCT01267864 | Phase 4 | Completed | 330 | IV ketorolac vs. IV metoclopramide vs. IV valproate for acute migraine |
| NCT01011673 | Phase 4 | Completed | 123 | Metoclopramide/diphenhydramine vs. ketorolac alone for tension-type headache in the ED |
| NCT01596166 | Phase 4 | Completed | 56 | IV ketorolac + metoclopramide combination vs. monotherapy for pediatric migraine |
| NCT02664116 | Phase 4 | Unknown | 40 | IM ketorolac vs. oral diclofenac potassium (Cambia) for severe migraine |
| NCT03221569 | Phase 4 | Unknown | 60 | Sub-dissociative ketamine vs. ketorolac for tension-type headache |
| NCT05641363 | Phase 3 | Completed | 171 | Comparison of ketorolac at three doses in children with acute pain |
| NCT06083571 | Phase 2 | Terminated | 41 | Intranasal ketorolac + oral prochlorperazine/diphenhydramine vs. IV standard regimen for pediatric migraine |
Literature Evidence
(Top 10 of 19 publications identified, prioritizing guidelines/RCTs/systematic reviews)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41321235 | 2026 | Guideline | Headache | AHS 2025 guideline update on parenteral pharmacotherapy for acute migraine in the ED, including ketorolac |
| 39674934 | 2025 | Systematic Review/Meta-analysis | Annals of Emergency Medicine | Bayesian network meta-analysis ranking pharmacologic therapies for ED migraine efficacy/safety |
| 35670115 | 2022 | RCT | Headache | Randomized trial of IV metoclopramide vs. metoclopramide + ketorolac for pediatric migraine in the ED |
| 35138658 | 2022 | Systematic Review/Meta-analysis | Academic Emergency Medicine | Efficacy of parenteral ketorolac for acute migraine attack |
| 30783794 | 2019 | RCT | Neurological Sciences | Double-blind RCT comparing dexamethasone, metoclopramide, ketorolac, and chlorpromazine for migraine pain relief and recurrence prevention |
| 37849443 | 2024 | Systematic Review/Meta-analysis | Adv Clin Exp Med | Updated meta-analysis of IV ketorolac vs. metoclopramide for adult migraine |
| 25600718 | 2015 | Review | Headache | AHS evidence assessment of migraine pharmacotherapies |
| 24875925 | 2015 | Guideline/Review | Cephalalgia | Canadian Headache Society systematic review and recommendations for treating migraine pain in the ED |
| 9484382 | 1998 | RCT | Neurology | Controlled trial of IM ketorolac vs. meperidine+promethazine vs. saline for tension-type headache |
| 1514724 | 1992 | RCT | Annals of Emergency Medicine | Randomized double-blind trial: ketorolac vs. meperidine+hydroxyzine for acute migraine |
Taiwan Market Information
Ketorolac currently holds 0 marketing authorizations in Taiwan (market_status: 未上市/Not marketed). No product licenses are on file for this evidence pack.
Additional Predicted Indications (Preliminary)
Two further indications were flagged by TxGNN for ketorolac but carry substantially weaker evidence than Headache Disorder:
| Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation | Notes |
|---|---|---|---|---|---|
| Rosacea Conjunctivitis | 99.40% | L5 | S0 | Hold | No clinical trials or literature identified; theoretical rationale only (possible topical NSAID anti-inflammatory effect), no ophthalmic development data exists |
| Trigeminal Autonomic Cephalalgia (e.g., cluster headache) | 99.39% | L4 | S1 | Research Question | 1 low-relevance withdrawn Phase 1 trial (procedural intervention, not ketorolac dosing) + 2 older literature items (1 review, 1 case report of ketorolac-lithium toxicity); shares trigeminovascular pain pathway with migraine but lacks direct efficacy data for this subtype |
Safety Considerations
Please refer to the package insert for safety information. Structured warnings, contraindications, and drug-interaction data were not available in this evidence pack (DDI query: not found).
Conclusion and Next Steps
Decision: Hold
Rationale: The Headache Disorder prediction is backed by an unusually strong and consistent evidence base (37 trials, 19 publications including a 2026 specialty-society guideline), largely reconfirming ketorolac's established off-label use in emergency migraine/tension-headache management. However, a Blocking-severity data gap exists: TFDA/package-insert warnings and contraindications are unavailable, which prevents even an initial (S1) safety evaluation, and the drug is not currently marketed in Taiwan (0 authorizations). Efficacy evidence alone cannot justify advancing past Hold until the safety data gap is closed.
To proceed, the following is needed:
- TFDA (or equivalent) package insert with warnings/contraindications (DG001, Blocking)
- Confirmed mechanism-of-action documentation from DrugBank (DG002, High)
- A defined regulatory pathway given ketorolac's current "not marketed" status in Taiwan
- Individual relevance grading of the 37 trials/19 papers (currently marked "pending") to confirm the L1 evidence-level classification
- If pursuing Trigeminal Autonomic Cephalalgia as a secondary research question, dedicated prospective trial data specific to that subtype
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.